BCCL picks up 6.25% stake in IRL
The News Review:
- BCCL picks up 6.25% stake in IRL
- Acro aims to slash drug research costs in half
- Lack of campaigning days bother students
- CMS Releases Clinical Trial Policy.(Centers for Medicare and Medicaid…
- Gene-Therapy Deaths Raise Ethics Issues
BCCL picks up 6.25% stake in IRL
Economic Times – Aug 30, 2007
7% to the total global clinical trials market of $26 billionand analysts expect India to contribute 30% of revenue by 2010. India is fastemerging as a destination for clinical trials as it provides diverse geneticpool and low-cost technical services the release added. ICRI society the clinicalresearch division of the group is a pioneer of clinical research education inIndia and is growing at over 100% annually. Currently ICRI has four campuses inDelhi Mumbai Bangalore and Ahmedabad. It is also exploring setting up campusesabroad and has a tie-up with Cranefield University (UK) for research &faculty support. getElementById(”storydiv”).
Acro aims to slash drug research costs in half
Business Report – Aug 30, 2007
open(new_location win_name win_opts);}. However medicine costs are not expected to decline due to cheaper research even though drug manufacturers and researchers are likely to pay less for access to study findings. Established this month Acro is a partnership between the government and the private sector. Its mandate is to make clinical research affordable to local firms academic institutions and non-governmental organisations (NGs). Lifelab a biotechnology unit of the department of science and technology represents the government while Batswadi Pharmaceuticals represents the private sector… However medicine costs are not expected to decline due to cheaper research even though drug manufacturers and researchers are likely to pay less for access to study findings. Established this month Acro is a partnership between the government and the private sector. Its mandate is to make clinical research affordable to local firms academic institutions and non-governmental organisations (NGs). Lifelab a biotechnology unit of the department of science and technology represents the government while Batswadi Pharmaceuticals represents the private sector. Current high costs mean most drugs used locally are developed overseas. The minimum cost of researching and manufacturing a new drug is $897 million (R6. 5 billion) according to a 2003 Tufts study.
Lack of campaigning days bother students
Hindu – Aug 30, 2007
“The students’ union leaders and the administration are in full agreement that all criminals and illegal elements should be removed from the halls of residence. The students have offered their cooperation in restoring peace on the campus and thus create a sense of confidence in the minds of a majority of the students of the University” said an AMU spokesperson. Head of Cranfield Health Cranfield University Joe Lunec recently inaugurated the second batch of M. programme in Clinical Research at the Delhi campus of the Institute of Clinical Research (ICRI). He also announced the start of a new two-year M.
CMS Releases Clinical Trial Policy.(Centers for Medicare and Medicaid…
Free with registration – Mondaq Business Briefing – AccessMyLibrary.com – Aug 30, 2007
This alert summarizes the revisions and discusses how those revisions deviate from the original policy. Background The original CTP NCD1 issued by CMS’ predecessor (the Health Care Financing Administration) in 2000 specified the circumstances an item or service would be considered reasonable and necessary and therefore payable by Medicare when provided to a beneficiary in the context of a clinical trial. The CTP lists three requirements of a qualified clinical trial: The subject or purpose of the trial must be the evaluation of an item or service that falls within a. CPYRIGHT 2007 Mondaq Ltd.
Gene-Therapy Deaths Raise Ethics Issues
Wired News – Aug 30, 2007
In light of the numerous problems linked to gene-therapy studies experts say that patients should be very cautious when considering enrollment in such a trial especially if the disease is not life-threatening or is under control with available medication. The FDA has not announced plans to review its criteria for evaluating the trials and the agency did not respond to repeated requests for comment by press time.
Written by admin on August 30th, 2007 with
no comments.
Read more articles on News.